Article 1
Annex VI to Regulation (EC) No 1272/2008 is amended as set out in the Annex to this Regulation.
Commission Delegated Regulation (EU) 2024/197 of 19 October 2023 amending Regulation (EC) No 1272/2008 as regards the harmonised classification and labelling of certain substances
Commission Delegated Regulation (EU) 2024/197 of 19 October 2023 amending Regulation (EC) No 1272/2008 as regards the harmonised classification and labelling of certain substances
Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗
Article 2
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union . It shall apply from 1 September 2025. However, suppliers may already before that date classify, label and package substances and mixtures in accordance with Regulation (EC) No 1272/2008 as amended by this Regulation.
Supplementary provisions
ANNEXSupplementary provisions
ANNEX In Annex VI to Regulation (EC) No 1272/2008, Table 3 of Part 3 is amended as follows: (1) the following entries are inserted following the order of the index numbers corresponding to each entry: Index No Chemical Name EC No CAS No Classification Labelling Specific Conc. Limits, M- factors and ATE Notes Hazard Class and Category Code(s) Hazard statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s) ‘015-204-00-5 benzyl(diethylamino)diphenylphosphonium 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]phenolate 479-100-5 577705-90-9 Repr. 1B H360F GHS08 Dgr H360F’ ‘015-205-00-0 benzyltriphenylphosphonium, salt with 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]bis[phenol] (1:1) 278-305-5 75768-65-9 Repr. 1B H360F GHS08 Dgr H360F’ ‘015-206-00-6 reaction mass of 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol and benzyl(diethylamino)diphenylphosphonium 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]phenolate (1:1) — — Repr. 1B H360F GHS08 Dgr H360F’ ‘015-207-00-1 reaction mass of 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol and benzyltriphenylphosphonium, salt with 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol (1:1) — — Repr. 1B H360F GHS08 Dgr H360F’ ‘015-208-00-7 dimethyl propylphosphonate 242-555-3 18755-43-6 Muta. 1B Repr. 1B H340 H360Df GHS08 Dgr H340 H360Df’ ‘050-034-00-5 dibutyltin maleate 201-077-5 78-04-6 Muta. 2 Repr. 1B Acute Tox. 2 Acute Tox. 4 STOT RE 1 Skin Corr. 1 Eye Dam. 1 H341 H360FD H330 H302 H372 (immune system) H314 H318 GHS08 GHS06 GHS05 Dgr H341 H360FD H330 H302 H372 (immune system) H314 inhalation: ATE = 0,317 mg/L (dusts or mists) oral: ATE = 510 mg/kg bw’ ‘050-035-00-0 dibutyltin oxide 212-449-1 818-08-6 Muta. 2 Repr. 1B Acute Tox. 3 STOT RE 1 Skin Irrit. 2 Eye Dam. 1 H341 H360FD H301 H372 (immune system) H315 H318 GHS08 GHS06 GHS05 Dgr H341 H360FD H301 H372 (immune system) H315 H318 oral: ATE = 170 mg/kg bw’ ‘603-244-00-1 reaction mass of 1-(2,3-epoxypropoxy)–2,2-bis ((2,3-epoxypropoxy)methyl) butane and 1-(2,3-epoxypropoxy)-2-((2,3-epoxypropoxy)methyl)-2-hydroxymethyl butane — — Muta. 2 Repr. 1B H341 H360F GHS08 Dgr H341 H360F’ ‘603-245-00-7 2,2'-[[3-methyl-4-[(4-nitrophenyl)azo]phenyl]imino]bisethanol 221-665-5 3179-89-3 Skin Sens. 1 H317 GHS07 Wng H317’ ‘603-246-00-2 3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctan-1-ol 211-477-1 647-42-7 STOT RE 2 Aquatic Chronic 1 H373 (teeth, bones) H410 GHS08 GHS09 Wng H373 (teeth, bones) H410 M = 1’ ‘604-099-00-7 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol; bisphenol AF 216-036-7 1478-61-1 Repr. 1B H360F GHS08 Dgr H360F’ ‘604-100-00-0 nonylphenol, branched and linear, ethoxylated (with average molecular weight ≤ 1 540 g/mol) [includes ortho-, meta-, para- isomers or any combination thereof] 500-315-8 500-024-6 500-045-0 500-209-1 248-762-5 243-816-4 248-291-5 — 230-770-5 248-743-1 247-555-7 248-293-6 — and others 127087-87-0 9016-45-9 26027-38-3 68412-54-4 27986-36-3 20427-84-3 27176-93-8 1119449-38-5 7311-27-5 27942-27-4 26264-02-8 27177-05-5 14409-72-4 and others Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410 M = 1 M = 10’ ‘606-155-00-6 cinnamaldehyde; 3-phenylprop-2-enal; cinnamic aldehyde; cinnamal; [1] (2 E )-3-phenylprop-2-enal [2] 203-213-9 [1] - [2] 104-55-2 [1] 14371-10-9 [2] Skin Sens. 1A H317 GHS07 Wng H317 Skin Sens. 1; H317: C ≥ 0,01 %’ ‘607-766-00-0 tetramethylene dimethacrylate 218-218-1 2082-81-7 Skin Sens. 1B H317 GHS07 Wng H317’ ‘607-767-00-6 7,7,9(or 7,9,9)-trimethyl–4,13-dioxo–3,14-dioxa–5,12-diazahexadecane–1,16-diyl bismethacrylate 276-957-5 72869-86-4 Skin Sens. 1B H317 GHS07 Wng H317’ ‘607-768-00-1 2,2'-ethylenedioxydiethyl dimethacrylate 203-652-6 109-16-0 Skin Sens. 1B H317 GHS07 Wng H317’ ‘607-769-00-7 bifenox (ISO); methyl 5-(2,4-dichlorophenoxy)-2-nitrobenzoate 255-894-7 42576-02-3 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 H302 H400 H410 GHS07 GHS09 Wng H302 H410 oral: ATE = 1 500 mg/kg bw M = 1 000 M = 1 000 ’ ‘612-295-00-9 benfluralin (ISO); N -butyl- N -ethyl-α,α,α-trifluoro-2,6-dinitro- p -toluidine 217-465-2 1861-40-1 Carc. 2 Repr. 2 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H351 H361d H315 H319 H317 H400 H410 GHS08 GHS07 GHS09 Wng H351 H361d H315 H319 H317 H410 M = 10 M = 10’ ‘612-296-00-4 N,N -dimethyl- p -toluidine 202-805-4 99-97-8 Carc. 1B Acute Tox. 4 Acute Tox. 3 STOT RE 2 Aquatic Chronic 3 H350 H332 H301 H373 (blood system, respiratory tract) H412 GHS08 GHS06 Dgr H350 H332 H301 H373 (blood system, respiratory tract) H412 inhalation: ATE = 1,4 mg/L (dusts or mists) oral: ATE = 140 mg/kg bw’ ‘612-297-00-X 1-phenylethan-1-one (1-phenylethylidene)hydrazone 211-979-0 729-43-1 Skin Sens. 1 H317 GHS07 Wng H317’ ‘612-298-00-5 1,4-Benzenediamine, N,N’ -mixed Ph and tolyl derivs.; 273-227-8 68953-84-4 Repr. 1B Skin Sens. 1 H360FD H317 GHS08 GHS07 Dgr H360FD H317’ ‘613-346-00-8 4-nitrosomorpholine — 59-89-2 Carc. 1B Muta. 2 STOT RE 1 H350 H341 H372 (liver) GHS08 Dgr H350 H341 H372 (liver) Carc. 1B; H350: C ≥ 0,001 %’ ‘613-347-00-3 difenoconazole (ISO); 1-({2-[2-chloro-4-(4-chlorophenoxy)phenyl]-4-methyl–1,3-dioxolan-2-yl}methyl)-1H-1,2,4-triazole; 3-chloro-4-[(2 RS ,4 RS ;2 RS ,4 SR )-4-methyl-2-(1 H -1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-2-yl]phenyl 4-chlorophenyl ether — 119446-68-3 Carc. 2 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 H351 H302 H319 H400 H410 GHS08 GHS07 GHS09 Wng H351 H302 H319 H410 oral: ATE = 1 450 mg/kg bw M = 10 M = 10’ ‘613-348-00-9 9-[2-(ethoxycarbonyl)phenyl]–3,6-bis(ethylamino)–2,7-dimethylxanthylium chloride; Basic Red 1 213-584-9 989-38-8 Acute Tox. 3 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H301 H318 H317 H400 H410 GHS06 GHS05 GHS09 Dgr H301 H318 H317 H410 oral: ATE = 280 mg/kg bw M = 10 M = 1’ ‘613-349-00-4 4-methylimidazole 212-497-3 822-36-6 Carc. 1B Repr. 1B H350 H360Fd GHS08 Dgr H350 H360Fd’ ‘615-051-00-X 3,3'-dimethylbiphenyl–4,4'-diyl diisocyanate 202-112-7 91-97-4 Carc. 2 Resp. Sens. 1 Skin Sens. 1A H351 H334 H317 GHS08 Dgr H351 H334 H317 Skin Sens. 1A; H317: C ≥ 0,001 %’ ‘616-241-00-5 foramsulfuron (ISO); 2-{[(4,6-dimethoxypyrimidin-2-yl)carbamoyl]sulfamoyl}-4-formamido- N,N -dimethylbenzamide; 1-(4,6-dimethoxypyrimidin-2-yl)-3-(2-dimethylcarbamoyl-5-formamidophenylsulfonyl)urea — 173159-57-4 Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 H351 H400 H410 GHS08 GHS09 Wng H351 H410 M = 1 000 M = 100’ ‘616-242-00-0 picolinafen (ISO); N -(4-fluorophenyl)-6-[3-(trifluoromethyl)phenoxy]pyridine-2-carboxamide; 4′-fluoro-6-[(α,α,α-trifluoro- m -tolyl)oxy]picolinanilide — 137641-05-5 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 H373 (blood system, thyroid) H400 H410 GHS08 GHS09 Wng H373 (blood system, thyroid) H410 M = 1 000 M = 1 000 ’ (2) the entries corresponding to index numbers 006-015-00-9; 015-203-00-X; 016-001-00-4; 016-011-00-9; 017-004-00-3; 017-005-00-9; 082-013-00-1; 082-014-00-7; 603-057-00-5; 604-010-00-1; 604-074-00-0; 606-034-00-8; 607-032-00-X; 607-034-00-0; 607-223-00-8; 607-246-00-3; 612-004-00-5; 612-049-00-0; 612-056-00-9; 613-088-00-6; 613-127-00-7; 613-307-00-5; 616-035-00-5; 616-104-00-X are replaced by the following entries respectively: Index No Chemical Name EC No CAS No Classification Labelling Specific Conc. Limits, M-factors and ATE Notes Hazard Class and Category Code(s) Hazard statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s) ‘006-015-00-9 diuron (ISO); 3-(3,4-dichlorophenyl)–1,1-dimethylurea 206-354-4 330-54-1 Carc. 1B STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 H350 H373 (blood system) H400 H410 GHS08 GHS09 Dgr H350 H373 (blood system) H410 M = 100 M = 100’ ‘015-203-00-X diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide 278-355-8 75980-60-8 Repr. 1B Skin Sens. 1B H360Fd H317 GHS08 GHS07 Dgr H360Fd H317’ ‘016-001-00-4 hydrogen sulphide, hydrogen sulfide 231-977-3 7783-06-4 Flam. Gas 1A Press. Gas Acute Tox. 2 Aquatic Acute 1 H220 H330 H400 GHS02 GHS06 GHS09 Dgr H220 H330 H400 inhalation: ATE = 440 ppmV (gases) U’ ‘016-011-00-9 sulphur dioxide; sulfur dioxide 231-195-2 7446-09-5 Press. Gas Acute Tox. 3 STOT SE 1 Skin. Corr. 1B H331 H370 (respiratory system) (inhalation) H314 GHS04 GHS06 GHS08 GHS05 Dgr H331 H370 (respiratory system) (inhalation) H314 inhalation: ATE = 1 000 ppmV (gases) U, 5’ ‘017-004-00-3 potassium chlorate 223-289-7 3811-04-9 Ox. Sol. 1 Acute Tox. 3 H271 H301 GHS03 GHS06 Dgr H271 H301 oral: ATE = 100 mg/kg bw’ ‘017-005-00-9 sodium chlorate 231-887-4 7775-09-9 Ox. Sol. 1 Acute Tox. 3 H271 H301 GHS03 GHS06 Dgr H271 H301 oral: ATE = 100 mg/kg bw’ ‘082-013-00-1 lead powder; [particle diameter < 1 mm] 231-100-4 7439-92-1 Repr. 1A Lact. Aquatic Acute 1 Aquatic Chronic 1 H360FD H362 H400 H410 GHS08 GHS09 Dgr H360FD H362 H410 Repr. 1A; H360D: C ≥ 0,03 % M = 10 M = 100’ ‘082-014-00-7 lead massive: [particle diameter ≥ 1 mm] 231-100-4 7439-92-1 Repr. 1A Lact. Aquatic Chronic 1 H360FD H362 H410 GHS08 GHS09 Dgr H360FD H362 H410 M = 10’ ‘603-057-00-5 benzyl alcohol 202-859-9 100-51-6 Acute Tox. 4 Eye Irrit. 2 Skin Sens. 1B H302 H319 H317 GHS07 Wng H302 H319 H317 oral: ATE = 1 200 mg/kg bw’ ‘604-010-00-1 resorcinol; 1,3-benzenediol 203-585-2 108-46-3 Acute Tox. 4 STOT SE 1 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1B Aquatic Acute 1 H302 H370 (nervous system) H315 H319 H317 H400 GHS07 GHS08 GHS09 Dgr H302 H370 (nervous system) H315 H319 H317 H400 oral: ATE = 500 mg/kg bw M = 1’ ‘604-074-00-0 2,2',6,6'-tetrabromo–4,4'-isopropylidenediphenol; tetrabromobisphenol-A 201-236-9 79-94-7 Carc. 1B Aquatic Acute 1 Aquatic Chronic 1 H350 H400 H410 GHS08 GHS09 Dgr H350 H410’ ‘606-034-00-8 metribuzin (ISO); 4-amino-6-tert-butyl-3-methylthio-1,2,4-triazin-5(4 H )-one; 4-amino-4,5-dihydro-6-(1,1-dimethylethyl)-3-methylthio-1,2,4-triazin-5-one 244-209-7 21087-64-9 Acute Tox. 4 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 H302 H373 (blood system) H400 H410 GHS07 GHS08 GHS09 Wng H302 H373 (blood system) H410 oral: ATE = 320 mg/kg bw M = 10 M = 10’ ‘607-032-00-X ethyl acrylate 205-438-8 140-88-5 Flam. Liq. 2 Acute Tox. 3 Acute Tox. 4 Acute Tox. 4 STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 H225 H331 H312 H302 H335 H315 H319 H317 GHS02 GHS06 Dgr H225 H331 H312 H302 H335 H315 H319 H317 inhalation: ATE = 9 mg/L (vapours) dermal: ATE = 1 800 mg/kg bw oral: ATE = 1 120 mg/kg bw STOT SE 3; H335: C ≥ 5 % Skin Irrit. 2; H315: C ≥ 5 % Eye Irrit. 2; H319: C ≥ 5 % D’ ‘607-034-00-0 methyl acrylate; methyl propenoate 202-500-6 96-33-3 Flam. Liq. 2 Acute Tox. 3 Acute Tox. 4 Acute Tox. 4 STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 H225 H331 H312 H302 H335 H315 H319 H317 GHS02 GHS06 Dgr H225 H331 H312 H302 H335 H315 H319 H317 inhalation: ATE = 3 mg/L (vapours) dermal: ATE = 1 100 mg/kg bw oral: ATE = 500 mg/kg bw D’ ‘607-223-00-8 transfluthrin (ISO); 2,3,5,6-tetrafluorobenzyl (1 R ,3 S )-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate 405-060-5 118712-89-3 Carc. 2 Acute Tox. 4 STOT SE 1 Aquatic Acute 1 Aquatic Chronic 1 H351 H302 H370 (nervous system) H400 H410 GHS08 GHS07 GHS09 Wng H351 H302 H370 (nervous system) H410 EUH066 oral: ATE = 580 mg/kg bw M = 1 000 M = 1 000 ’ ‘607-246-00-3 allyl methacrylate; 2-methyl-2-propenoic acid 2-propenyl ester 202-473-0 96-05-9 Flam. Liq. 3 Acute Tox. 2 Acute Tox. 3 Acute Tox. 4 Aquatic Acute 1 H226 H330 H311 H302 H400 GHS02 GHS06 GHS09 Dgr H226 H330 H311 H302 H400 inhalation: ATE = 1,5 mg/L (vapours) dermal: ATE = 300 mg/kg bw oral: ATE = 400 mg/kg bw’ ‘612-004-00-5 triethylamine 204-469-4 121-44-8 Flam. Liq. 2 Acute Tox. 3 Acute Tox. 3 Acute Tox. 3 Skin Corr. 1A Eye Dam. 1 H225 H331 H311 H301 H314 H318 GHS02 GHS06 GHS05 Dgr H225 H331 H311 H301 H314 inhalation: ATE = 7,2 mg/L (vapours) dermal: ATE = 300 mg/kg bw oral: ATE = 100 mg/kg bw STOT SE 3; H335: C ≥ 1 %’ ‘612-049-00-0 di- n -butylamine 203-921-8 111-92-2 Flam. Liq. 3 Acute Tox. 2 Acute Tox. 3 Acute Tox. 3 Skin Corr. 1B Eye Dam. 1 H226 H330 H311 H301 H314 H318 GHS02 GHS06 GHS05 Dgr H226 H330 H311 H301 H314 EUH 071 inhalation: ATE = 1,2 mg/L (vapours) dermal: ATE = 300 mg/kg bw oral: ATE = 220 mg/kg bw’ ‘612-056-00-9 N , N -dimethyl-m-toluidine; [1] N , N -dimethyl-o-toluidine [2] 204-495-6 [1] 210-199-8 [2] 121-72-2 [1] 609-72-3 [2] Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Chronic 3 H331 H311 H301 H373 ** H412 GHS06 GHS08 Dgr H331 H311 H301 H373 ** H412 * C’ ‘613-088-00-6 1,2-benzisothiazol-3(2H)-one; 1,2-benzisothiazolin-3-one 220-120-9 2634-33-5 Acute Tox. 2 Acute Tox. 4 Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 H330 H302 H315 H318 H317 H400 H410 GHS06 GHS05 GHS09 Dgr H330 H302 H315 H318 H317 H410 inhalation: ATE = 0,21 mg/L (dusts or mists) oral: ATE = 450 mg/kg bw Skin Sens. 1A; H317: C ≥ 0,036 % M = 1 M = 1’ ‘613-127-00-7 mepiquat chloride (ISO); 1,1-dimethylpiperidinium chloride 246-147-6 24307-26-4 Acute Tox. 4 Acute Tox. 3 Aquatic Chronic 3 H332 H301 H412 GHS06 Dgr H332 H301 H412 inhalation: ATE = 2,8 mg/L (dusts or mists) oral: ATE = 270 mg/kg bw’ ‘613-307-00-5 clothianidin (ISO); (E)-1-(2-chloro–1,3-thiazol-5-ylmethyl)-3-methyl-2-nitroguanidine 433-460-1 210880-92-5 Repr. 2 Acute Tox. 4 STOT SE 1 Aquatic Acute 1 Aquatic Chronic 1 H361f H302 H370 (nervous system) H400 H410 GHS08 GHS07 GHS09 Dgr H361f H302 H370 (nervous system) H410 oral: ATE = 390 mg/kg bw M = 10 M = 100’ ‘616-035-00-5 cymoxanil (ISO); 2-cyano- N -[(ethylamino)carbonyl]-2-(methoxyimino)acetamide; [1] (2 E )-2-cyano- N -[(ethylamino)carbonyl]-2-(methoxyimino)acetamide; [2] 261-043-0 [1] - [2] 57966-95-7 [1] 166900-80-7 [2] Repr. 2 Acute Tox. 4 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H361fd H302 H373 (blood system, thymus, eyes) H317 H400 H410 GHS08 GHS07 GHS09 Wng H361fd H302 H373 (blood system, thymus, eyes) H317 H410 oral: ATE = 360 mg/kg bw M = 1 M = 1’ ‘616-104-00-X benalaxyl (ISO); methyl N -(2,6-dimethylphenyl)- N -(phenylacetyl)-DL-alaninate 275-728-7 71626-11-4 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 H302 H400 H410 GHS07 GHS09 Wng H302 H410 oral: ATE = 1 000 mg/kg bw M = 1 M = 1’
Other acts of the same type
Commission Implementing Regulation (EU) 2015/1471 of 24 August 2015 approving non-minor amendments to the specification for a name entered in the register of protected designations of origin and protected geographical indications (Olives noires de Nyons (PDO))Commission Implementing Regulation (EU) 2015/1414 of 20 August 2015 amending Implementing Regulation (EU) No 136/2012 concerning the authorisation of sodium bisulphate as feed additive for pets and for non-food producing animals (Text with EEA relevance)Commission Implementing Regulation (EU) 2015/1415 of 20 August 2015 concerning the authorisation of astaxanthin as a feed additive for fish, crustaceans and ornamental fish (Text with EEA relevance)Commission Implementing Regulation (EU) 2015/1416 of 20 August 2015 concerning the authorisation of sodium bisulphate as feed additive for all animal species (Text with EEA relevance)Commission Implementing Regulation (EU) 2015/1417 of 20 August 2015 concerning the authorisation of diclazuril as a feed additive for rabbits for fattening and for breeding (holder of the authorisation Huvepharma NV) (Text with EEA relevance)Commission Implementing Regulation (EU) 2015/1424 of 20 August 2015 approving non-minor amendments to the specification for a name entered in the register of protected designations of origin and protected geographical indications (Pomme du Limousin (PDO))Commission Implementing Regulation (EU) 2015/1407 of 19 August 2015 amending Implementing Regulation (EU) No 170/2013 laying down transitional measures in the sugar sector by reason of the accession of CroatiaCommission Implementing Regulation (EU) 2015/1408 of 19 August 2015 concerning the authorisation of DL-methionyl-DL-methionine as a feed additive for fish and crustaceans (Text with EEA relevance)Commission Implementing Regulation (EU) 2015/1403 of 18 August 2015 withdrawing the acceptance of the undertaking for one exporting producer under Implementing Decision 2013/707/EU confirming the acceptance of an undertaking offered in connection with the anti-dumping and anti-subsidy proceedings concerning imports of crystalline silicon photovoltaic modules and key components (i.e. cells) originating in or consigned from the People's Republic of China for the period of application of definitive measuresCommission Implementing Regulation (EU) 2015/1399 of 17 August 2015 concerning the denial of authorisation of the preparation of Bacillus toyonensis (NCIMB 14858T) (formerly Bacillus cereus var. toyoi NCIMB 40112/CNCM I-1012) as a feed additive for cattle for fattening, rabbits for fattening, chickens for fattening, piglets (weaned), pigs for fattening, sows for reproduction and calves for rearing and the revocation of the authorisations of the preparation of Bacillus cereus var. toyoi (NCIMB 40112/CNCM I-1012) as a feed additive for turkeys for fattening and rabbit breeding does, amending Regulations (EC) No 256/2002, (EC) No 1453/2004, (EC) No 255/2005 and (EC) No 1200/2005 and repealing Regulations (EC) No 166/2008, (EC) No 378/2009 and Implementing Regulation (EU) No 288/2013 (Text with EEA relevance)Commission Implementing Regulation (EU) 2015/1396 of 14 August 2015 correcting Implementing Regulation (EU) No 540/2011 as regards the active substance Bacillus subtilis (Cohn 1872) strain QST 713, identical with strain AQ 713 (Text with EEA relevance)Commission Implementing Regulation (EU) 2015/1397 of 14 August 2015 renewing the approval of the active substance florasulam in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council concerning the placing of plant protection products on the market, and amending the Annex to Commission Implementing Regulation (EU) No 540/2011 (Text with EEA relevance)
Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.
What to look at next
Browse all EU Legal ActsEvery instrument by type and year, full text free to read section by sectionEuropean Union legislationEU Legal Acts by type and yearGrouped by instrument type and year of enactment, so you can find others of the same kindBrowse by type and yearEuropean Union: what this database coversWhich datasets are here, which official source they come from, and how current they areEuropean Union overview